Dr Rohlff has approximately 20 years’ commercial, business development and intellectual property experience gained in the international biotechnology industry. He became Chief Executive of Oxford BioTherapeutics in 2004, after founding the company and acquiring targeting technology, bioinformatics data and intellectual property from Oxford GlycoSciences, following its acquisition by Celltech. Prior to this, as Director of Oxford GlycoSciences’ proteomics collaborations, he led the company’s partnerships in oncology and other serious diseases with leading pharmaceutical companies and institutions, including Pfizer, GSK, Bayer, Wyeth, Takeda, the Cystic Fibrosis Foundation, Oxford University and the FDA. Previously, he held a number of positions at the US National Cancer Institute. Dr Rohlff holds a PhD from the Department of Pharmacology at Georgetown University.
Christian Rohlff, PhD
Chief Executive Officer
Carmel Lynch, PhD
Senior Vice President, Non-clinical Development
Dr Carmel Lynch has over 20 years’ R&D experience in the international biotechnology industry. Most recently, she was Senior Director at Seattle Genetics where she led the non-clinical science and clinical pharmacology work for the approval of the oncology antibody-drug conjugate, ADCETRIS®. Prior to joining Seattle Genetics, she was Director of Non-clinical Development at Corixa where she supported a number of clinical and research programs. Previously, she held a number of roles at Targeted Genetics Corporation, including Director of Pre-clinical Biology. Dr Lynch holds a PhD in Pharmacology from University College Dublin, and conducted post-doctoral research at the Fred Hutchinson Cancer Research Center in Seattle.
Salvatore Febbraro, MD
Senior Medical Director
Dr Salvatore Febbraro has over 20 years’ experience in pharmaceutical medicine, exploratory and confirmatory clinical development. He held several medical positions in global biopharmaceutical companies and CROs. Dr Febbraro served as Medical Director in the AstraZeneca Phase 1 Unit where as Principal Investigator, he was responsible for the clinical conduct of several studies testing novel and targeted agents. He has been a PI for over 100 FIH / Phase 1 clinical trials and has led clinical pharmacology units and multidisciplinary teams in the UK and Canada.
A graduate from the University of Naples Medical School, he has worked as a Clinician and Hospital Physician in Italy and the UK before joining the pharmaceutical industry and clinical trials research.
Senior Vice President, Protein Sciences
Tom Boone joined Oxford BioTherapeutics from Amgen, where he gained nearly 30 years’ experience in a variety of roles. Most recently, he headed Amgen’s expression, purification, and characterization teams within the company’s research group, which went on to become the Protein Science group. Previously, he played a key role as a scientist and Director in the development of many of Amgen’s processes, including for Neupogen. He began his career at the company as a Research Associate, cloning and sequencing genes, including G-CSF (Neupogen).
Senior Director, Finance
Scott Sandler has over 20 years of finance experience in the biotechnology sector. Most recently, he was Senior Director at Hyperion Therapeutics, a pharmaceutical company focused on orphan diseases. Previously, he held financial roles of increasing responsibility at a number of companies including Ipsen, Nektar Therapeutics, and Genentech. He started his career in the process development labs at Biogen. He holds a BSE in engineering from Tufts University and an MBA from the University of Michigan.
Human Resources Director
Danai Pampiglione’s career in human resource management spans more than 25 years; she has worked in a wide range of organisations including the NHS, KLM Royal Dutch Airlines, the University of Reading as well as in housing and professional services. Danai joined Oxford BioTherapeutics in 2016 from The Fertility Partnership, the UK’s leading provider of IVF and fertility treatment. Her experience also encompasses 6 years at Oxford GlycoSciences Plc – the progenitor of Oxford BioTherapeutics. She is a Chartered Member of the CIPD and holds a Masters in HR Strategy.
Robert Boyd, PhD
UK Site Head and Scientific Director
Dr Robert Boyd has over 20 years of experience in therapeutic antibody target discovery. He also has expertise in the application of cutting edge mass spectrometry to all stages of the drug discovery process. Dr Boyd joined OBT from the MRC Toxicology Unit where he was a senior investigator identifying novel lymphoma targets. He was previously head of proteome biology at Oxford GlycoSciences Plc where he led a team engaged in high throughput oncology target discovery and validation. Dr Boyd holds a PhD in Biochemistry from Sussex University, and conducted post-doctoral research at the Royal Postgraduate Medical School and the Imperial Cancer Research Fund.